MedPath

Osteoporosis and Dental Implant

Phase 4
Conditions
Osteoporosis
Interventions
Registration Number
NCT00727493
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

The purpose of this study is to evaluate the influence of alendronate therapy on the wound healing after dental implants in patients with osteoporosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
45
Inclusion Criteria
  • Postmenopausal women > 2 years after menopause
  • Age between 60 and 75 years
  • Possibility to insert a dental implant
  • Osteoporosis as defined by WHO criteria (intervention group), or women without osteoporosis / osteopenia (non-intervention group)
Exclusion Criteria
  • Pathological findings in the jaw bone
  • Chronic inflammatory rheumatoid disease
  • Bisphosphonate treatments during the last 12 months
  • Inflammatory or metabolic bone disease, excluding osteoporosis
  • Systemic corticosteroid treatments of more than one month within previous 12 months
  • Severe diseases with life expectancy less than one year or expectation of rapid worsening within one year

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1alendronate once weekly 70mgalendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
2placeboplacebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
Primary Outcome Measures
NameTimeMethod
Dental CTbaseline, and 3,6,12 months after baseline
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath